The Pharmacological Costs for the Management of Skin Toxicity in Patients With Cancer Treated With Epidermal Growth Factor Receptor-Inhibitors
Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non–Small-cell Lung Cancer
EGFR Testing in Advanced Non–Small-Cell Lung Cancer, A Mini-Review
Incorporation of Antiangiogenic Therapy Into the Non–Small-Cell Lung Cancer Paradigm
Circulating Biomarkers in Non–Small-Cell Lung Cancer: Current Status and Future Challenges
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma
Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit
Progression-Free and Overall Survival of Patients With ALK Rearrangement–Positive Non–Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib
Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer
Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non–Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group
Optimizing Survival of Patients With Marginally Operable Stage IIIA Non–Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery
A Survival Score for Patients Receiving Palliative Irradiation for Locally Advanced Lung Cancer
Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non–small-Cell Lung Cancer
Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment
Prognostic Factor Analysis in Patients With Small-Cell Lung Cancer Treated With Third-Line Chemotherapy
Hypofractionated Intensity-Modulated Radiotherapy for Patients With Non–Small-Cell Lung Cancer
Stereotactic Body Radiotherapy for T3N0 Lung Cancer With Chest Wall Invasion
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non–Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405)